When something is working extremely well, we should demand very compelling evidence before changing it. I believe that’s why a recent Ipsos survey on meningococcal meningitis ...

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.